Celgene — Shareholder Meeting (May 2014)
21 slides from Celgene's shareholder meeting presentation, May 20, 2014
Slide 1: Schedule 14A Proxy Statement - Celgene Corporation
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy
Slide 2: Schedule 14A filing fee section
(5) Total fee paid: ¨ Fee paid previously with preliminary materials. ¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or t
Slide 3: Additional 2014 Proxy Materials
Additional 2014 Proxy Materials Celgene (NASDAQ: CELG)
Slide 4: Forward Looking Statements and Non-GAAP Financial Information
Forward Looking Statements and Non-GAAP Financial Information This presentation contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “
Slide 5: Agenda
Agenda • Celgene Overview • Proposal to Amend the 2008 Equity Plan • Stockholder Proposal on Disclosure of Political Activity 3
Slide 6: We Are a Leading Global Biopharmaceutical Company
We Are a Leading Global Biopharmaceutical Company Global, Fully Portfolio of Unique R&D Integrated Leading Products Capability • Operations in >50 • Expertise in countries hematology, oncology, and immunology • Sales in >70 countries • Diverse technology • Manufacturing facilities platforms in US an
Slide 7: We Have a Strong 5-Year Financial Track Record
We Have a Strong 5-Year Financial Track Record 1 Net Product Sales ($B) Adjusted Margins 48.4% ~25% 41.0% CAGR 2 $6.4 $5.4 26.0% R&D $4.7 23.4% 25.4% $3.5 SG&A 23.2% $2.6 COGS 8.0% 5.1% 2009 2010 2011 2012 2013 2009 2010 2011 2012 2013 Adjusted EPS ($) $5.96 ~31% $4.91 CAGR2 $3.79 $2.79 $2.08 2009 2
Slide 8: Our Performance Has Led to Significant Value Creation
Our Performance Has Led to Significant Value Creation Celgene Performance Relative to Key Indices CELG NBI BTK COMP SPX 1-year 115% 66% 51% 38% 30% 3-year 186% 144% 80% 57% 47% 5-year 206% 225% 260% 165% 105% 10-year 1406% 227% 376% 108% 66% Note: Periods are for calendar year; amounts based on quot
Slide 9: Recent Operational Achievements Are Expected to Sustain Our Growth Profile Through 2017
Recent Operational Achievements Are Expected to Sustain Our Growth Profile Through 2017 Net Product Sales ($B) Key Operational Achievements $13-$14 ~21% Launched 2 New Products CAGR POMALYST ®/IMNOVID® for 3rd-line+ $8.5-$9.5 multiple myeloma in the U.S. and Europe OTEZLA® for psoriatic arthritis in
Slide 10: Our Equity Plan Is a Critical Tool to Delivering on Our 2017 Financial Targets
Our Equity Plan Is a Critical Tool to Delivering on Our 2017 Financial Targets The primary purpose of the Plan is to enable us to attract, retain, and motivate key employees who are important to our success by aligning their interests with those of our stockholders. Our Plan has broad participation
Slide 11: The Plan Has Several Stockholder-Friendly Features
The Plan Has Several Stockholder-Friendly Features The Plan has several features designed to protect stockholder interests and promote effective corporate governance, including: The Plan is administered by the Compensation Committee comprised solely of independent directors Stock options have a term
Slide 12: We Are Requesting 9 Million Additional Shares for the Equity Plan
We Are Requesting 9 Million Additional Shares for the Equity Plan Stockholders are being asked to approve an amendment to our 2008 Stock Incentive Plan that includes the following key modifications: Increase the current share reserve by 9,000,000 shares (pre-split) of our Common Stock Extend the ter
Slide 13: Our Strong Performance Has Created a Significant Overhang with In-the-Money Options
Our Strong Performance Has Created a Significant Overhang with In-the-Money Options Outstanding Stock Option Awards at Record Date • Celgene employees have a history of holding onto their awards, creating a pool of exercisable options that are significantly in-the-money Weighted Avg. Year Granted Op
Slide 14: Proposal Six: Stockholder Proposal for Increased Disclosure on Political Contributions
Proposal Six: Stockholder Proposal for Increased Disclosure on Political Contributions American Federation of State, County and Municipal Employees, AFL-CIO, (AFSCME) submitted Proposal Six requesting the Board to authorize the preparation of an annual report disclosing: 1. Company policy and proced
Slide 15: We Recommend Voting Against Proposal Six
We Recommend Voting Against Proposal Six Our Board believes that this proposal is unnecessary and would not serve the interests of Celgene stockholders because our Company already makes extensive disclosures about our lobbying activities and the additional information requested by this proposal woul
Slide 16: Conclusion
Conclusion • We are a leading biopharmaceutical company with an exceptional track record of value creation resulting in strong stock price outperformance • Based on operational achievements we expect to sustain our growth profile through 2017 and beyond • Our Equity Plan is a critical component in o
Slide 17: Additional 2014 Proxy Materials
Additional 2014 Proxy Materials Celgene (NASDAQ: CELG)
Slide 18: Reconciliation Tables
(ob) #1 wT az $s at S$ iP %S s pred Cd vl uz bid s st S$ Ms ay $ tq ne) postipy - 203325 01 agemquye 2209s uxuw03 sad au 12K, ic S¥IL Te soit $ 6mtl S$ Smt lost $ ovary » 20382) oF granu suncus 32K, om) {69) env (ree) (O60) ey) a srasaastipe Xt) a0 1N, c (go) ko) spare 203-008 suey 12) saan _— (40)
Slide 19: Reconciliation Tables
Reconciliation Tables Celgene Corporation and Subsidiaries Reconciliation of GAAP to Adjusted Net Income Explanation of adjustments: (1) Exclude sales related to non-core former Pharmion Corp., or Pharmion, and Abraxis BioScience Inc., or Abraxis products to be divested. (2) Exclude the estimated im
Slide 20: ROIC Calculation
Celgene ROIC Calculation Retum on Invested Capital (ROIC) 2013 2012 2011 2010 2009 2008 Operating income 7,808,000 1,746,442 1.442.753 980.625 841.526 (1.464.218) Certain charges (1) 2,043,060 Operating income (non-GAAP for 2008) 1,808,000 1,746,442 1,442,753 989,635 841,526 578,851 Effective tax ra
Slide 21: Important Notice Regarding the Availability of Proxy Materials
Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders to be held on June 18, 2014: The Proxy Statement, a sample of the form of proxy card sent or given to stockholders by Celgene Corporation, and the Annual Report to Stockholders are available at http